InterMune, Inc.

BRISBANE, Calif., June 14, 2013 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced that the Board of the Italian Drug Agency (AIFA) has approved the pricing and reimbursement conditions for Esbriet(®) (pirfenidone), and that the agreement has been published in the Official Gazette, the official journal ... read more

BRISBANE, Calif., April 17, 2013 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced that it will release its first quarter 2013 financial results at the close of the U.S. markets on Wednesday, April 24, 2013. A live conference call and webcast will be hosted by InterMune ... read more

BRISBANE, Calif., March 20, 2013 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today reported that the National Institute for Health and Clinical Excellence (NICE), the health technology appraisal body in England and Wales, has issued its Final Appraisal Determination (FAD) recommending Esbriet(®) (pirfenidone) for the treatment ... read more

BRISBANE, Calif., Feb. 21, 2013 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced results from operations for the fourth quarter and full year ended December 31, 2012. (Logo: http://photos.prnewswire.com/prnh/20120827/SF62570LOGO) InterMune reported Esbriet(®) (pirfenidone) net revenue in the fourth quarter of 2012 of $8.2 million, compared with $2.7 million in the fourth quarter ... read more

BRISBANE, Calif., Feb. 14, 2013 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced that Sean P. Nolan has joined InterMune as Executive Vice President and Chief Business Officer. (Logo: http://photos.prnewswire.com/prnh/20120827/SF62570LOGO) In this newly created position, Mr. Nolan will lead the creation and establishment of InterMune's U.S. Commercial, Business ... read more

BRISBANE, Calif., Feb. 11, 2013 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced that it will release its fourth quarter and full-year 2012 financial results at the close of the U.S. markets on Thursday, February 21, 2013. A live conference call and webcast will be hosted ... read more

BRISBANE, Calif., Jan. 16, 2013 /PRNewswire/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that it has agreed to sell an aggregate of $105,000,000 principal amount of its 2.50% convertible senior notes due 2017 and 13,500,000 shares of its common stock at a price to the public of ... read more

BRISBANE, Calif., Jan. 14, 2013 /PRNewswire/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that it plans to offer, subject to market and other conditions, $85.0 million aggregate principal amount of convertible senior notes due 2017 and 12,500,000 shares of its common stock in concurrent underwritten public offerings. ... read more

BRISBANE, Calif., Jan. 3, 2013 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced unaudited net sales of Esbriet® (pirfenidone) for the fourth quarter ended December 31, 2012. The Company also highlighted recent business and clinical development activities, including completion of enrollment in the Phase 3 ASCEND trial, and provided forward-looking ... read more

BRISBANE, Calif., Jan. 2, 2013 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced that Dan Welch, Chairman, Chief Executive Officer and President of InterMune, will present at the 31st Annual J. P. Morgan Healthcare Conference in San Francisco on January 9, 2013, at 12:30 p.m. EST / ... read more